Celgene Corp (CELG) 103.41 $CELG
Stock Market News for July 07, 2016
Zacks Equity Research - Zacks Investment Research - Thu Jul 07, 9:10AM CDT
Benchmarks ended in the green on Wednesday after the FOMC minutes from June meeting showed that most of the Fed policymakers were in favor of keeping rates unchanged.
MDVN: 62.23 (+0.13), BIIB: 252.54 (+1.24), VRTX: 90.10 (+1.14), GILD: 86.25 (-0.30), UNH: 140.32 (-0.95), MRK: 59.34 (-0.01), ALXN: 125.30 (+0.88), XOM: 93.89 (+0.35), CVX: 105.39 (+0.62), REGN: 375.74 (-2.61), CELG: 103.41 (-1.62)
Biotechnology Equities Under the Scanner - Exelixis, Novavax, Celgene, and Ariad Pharma
PR Newswire - Thu Jul 07, 7:00AM CDT
On Wednesday, July 06, 2016, the NASDAQ Composite ended the trading session at 4,859.16, up 0.75%; the Dow Jones Industrial Average edged 0.44% higher, to finish at 17,918.62; and the S&P 500 closed at 2,099.73, up 0.54%. The gains were broad based as eight out of nine sectors ended the session in positive. Stock-Callers.com has initiated coverage on the following equities: Exelixis Inc. (NASDAQ: EXEL), Novavax Inc. (NASDAQ: NVAX), Celgene Corporation (NASDAQ: CELG), and Ariad Pharmaceuticals Inc. (NASDAQ: ARIA). Learn more about these stocks by accessing their free notes at:
NVAX: 7.77 (+0.15), ARIA: 7.37 (-0.14), CELG: 103.41 (-1.62), EXEL: 8.15 (unch), CELGZ: 1.40 (-0.03)
SmarTrend Watching for Potential Pullback in Shares of Celgene After 3.49% Gain
Comtex SmarTrend(R) - Wed Jul 06, 11:56AM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $100.13 to a high of $104.94. Yesterday, the shares gained 3.5%, which took the trading range above the 3-day high of $101.39 on volume of 3.9 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
CELG: 103.41 (-1.62)
Watch for Celgene to Potentially Pullback After Gaining 3.49% Yesterday
Comtex SmarTrend(R) - Wed Jul 06, 11:56AM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $100.13 to a high of $104.94. Yesterday, the shares gained 3.5%, which took the trading range above the 3-day high of $101.39 on volume of 3.9 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
CELG: 103.41 (-1.62)
Amgen's Kyprolis Gains Approval in EU for Label Expansion
Zacks Equity Research - Zacks Investment Research - Wed Jul 06, 9:37AM CDT
Amgen's (AMGN) Kyprolis label has been expanded in the EU for the treatment of relapsed multiple myeloma patients.
AMGN: 160.18 (-0.92), ABBV: 64.35 (+0.19), BMY: 75.39 (+0.11), CELG: 103.41 (-1.62)
Blog Coverage Biotech Major Medivation Open to Takeover Talks
ACCESSWIRE - Wed Jul 06, 8:15AM CDT
LONDON, UK / ACCESSWIRE / July 6, 2016 / Active Wall St. blog coverage looks at the headline from Medivation Inc. (NASDAQ: MDVN) as the U.S. company signs confidentiality agreements with Paris-based Sanofi S.A. (NYSE: SNY), Pfizer Inc. (NYSE: PFE) and Celgene Corp. (NASDAQ: CELG) among others. Register with us now for your free membership and blog access at:
MDVN: 62.23 (+0.13), PFE: 36.15 (+0.03), ABBV: 64.35 (+0.19), SNY: 41.42 (+0.57), CELG: 103.41 (-1.62)
After Yesterday's Rally of 2.09% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Fri Jul 01, 12:32PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $98.25 to a high of $101.39. Yesterday, the shares gained 2.1%, which took the trading range above the 3-day high of $99.42 on volume of 1.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
CELG: 103.41 (-1.62)
Celgene Rises 2.09% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Fri Jul 01, 12:30PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $98.25 to a high of $101.39. Yesterday, the shares gained 2.1%, which took the trading range above the 3-day high of $99.42 on volume of 1.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
CELG: 103.41 (-1.62)
How Does Brexit Impact Healthcare Stocks?
Arpita Dutt - Zacks Investment Research - Mon Jun 27, 8:34AM CDT
While Brexit does create economic uncertainty and there could be some near-term volatility in the sector, the general verdict is that Brexit's impact on drug stocks will be limited.
VRTX: 90.10 (+1.14), BMRN: 88.59 (-2.90), ALXN: 125.30 (+0.88), GSK: 43.52 (+0.14), CELG: 103.41 (-1.62)
Learn how to target an 20% return on Chipotle Mexican Grill, or get option-trade ideas on Amgen, Celgene, Google Inc., and SolarEdge Technologies or any stock you choose
PR Newswire - Thu Jun 23, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for AMGN, CELG, CMG, GOOG, and SEDG.
SEDG: 19.82 (+0.14), CMG: 403.18 (+3.47), AMGN: 160.18 (-0.92), GOOGL: 727.20 (+9.42), GOOG: 715.09 (+9.46), CELGZ: 1.40 (-0.03), CELG: 103.41 (-1.62)
Prima Reports Favorable Initial Breast Cancer Study Data
Zacks Equity Research - Zacks Investment Research - Wed Jun 22, 2:30PM CDT
Prima BioMed Ltd (PBMD) announced initial data from a phase IIb chemo-immunotherapy study on IMP321 for the treatment of metastatic breast cancer.
PBMD: 0.92 (unch), ANIP: 55.38 (-1.13), RTRX: 18.47 (-0.18), CELG: 103.41 (-1.62)
Four NCI Cancer Centers Announce Landmark Research Consortium and Collaborations with Celgene
BusinessWire - Wed Jun 22, 6:30AM CDT
Today, The Abramson Cancer Center at the University of Pennsylvania, The Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, and The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai announced the establishment of a research consortium focused on accelerating the discovery and development of novel cancer therapeutics and diagnostics for the benefit of patients.
CELG: 103.41 (-1.62)
Celgene Set to Possibly Rebound After Yesterday's Selloff of 2.17%
Comtex SmarTrend(R) - Tue Jun 21, 11:55AM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $96.55 to a high of $99.80. Yesterday, the shares fell 2.2%, which took the trading range below the 3-day low of $98.22 on volume of 4.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
CELG: 103.41 (-1.62)
Watch for Shares of Celgene (CELG) to Approach Resistance at $101.34
Comtex SmarTrend(R) - Mon Jun 20, 8:47AM CDT
Celgene (NASDAQ:CELG) has opened bullishly above the pivot of $99.13 today and has reached the first level of resistance at $100.04. Should the shares continue to rise, the resistance pivots of $101.34 and $103.55 will be of interest.
CELG: 103.41 (-1.62)
Company News for June 16, 2016
Zacks Equity Research - Zacks Investment Research - Thu Jun 16, 9:10AM CDT
Companies in the News are: BOBE,TWTR,PN,EBIX,CELG
PN: 7.80 (+0.14), BOBE: 36.33 (+0.32), EBIX: 52.12 (+2.98), TWTR: 17.71 (-0.37), CELG: 103.41 (-1.62)
Celgene Announces Additional $3 Billion Share Repurchase Authorization
BusinessWire - Wed Jun 15, 6:30AM CDT
Celgene Corporation (NASDAQ:CELG) today announced that during its June meeting the Company's Board of Directors authorized the repurchase of up to an additional $3.0 billion of the Company's common stock.
CELG: 103.41 (-1.62), CELGZ: 1.40 (-0.03)
SmarTrend Watching for Potential Rebound in Shares of Celgene After 2.63% Loss
Comtex SmarTrend(R) - Fri Jun 10, 12:32PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $103.26 to a high of $105.47. Yesterday, the shares fell 2.6%, which took the trading range below the 3-day low of $105.65 on volume of 2.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
CELG: 103.41 (-1.62)
Watch for Celgene to Potentially Rebound After Falling 2.63% Yesterday
Comtex SmarTrend(R) - Fri Jun 10, 12:30PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $103.26 to a high of $105.47. Yesterday, the shares fell 2.6%, which took the trading range below the 3-day low of $105.65 on volume of 2.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
CELG: 103.41 (-1.62)
Acceleron and Celgene Announce Updated Results from an Ongoing Phase 2 Study of Luspatercept in Myelodysplastic Syndromes at the 21st Congress of the European Hematology Association
BusinessWire - Fri Jun 10, 6:00AM CDT
--- Acceleron to host conference call and live webcast today at 8:00 a.m. EDT (2:00 p.m. CEST) -
XLRN: 34.35 (-0.40), CELGZ: 1.40 (-0.03), CELG: 103.41 (-1.62)
Celgene Announces Presentations of Investigational Studies in Blood Cancers at EHA 2016
BusinessWire - Thu Jun 09, 6:30AM CDT
Celgene Corporation (NASDAQ:CELG) today announced that more than 40 presentations reporting on investigational studies in blood cancers will be presented during the 21st European Hematology Association annual meeting in Copenhagen, Denmark, from June 9-12, 2016.
CELG: 103.41 (-1.62), CELGZ: 1.40 (-0.03)
Stock Market News for July 07, 2016
Zacks Equity Research - Zacks Investment Research - Thu Jul 07, 9:10AM CDT
Benchmarks ended in the green on Wednesday after the FOMC minutes from June meeting showed that most of the Fed policymakers were in favor of keeping rates unchanged.
MDVN: 62.23 (+0.13), BIIB: 252.54 (+1.24), VRTX: 90.10 (+1.14), GILD: 86.25 (-0.30), UNH: 140.32 (-0.95), MRK: 59.34 (-0.01), ALXN: 125.30 (+0.88), XOM: 93.89 (+0.35), CVX: 105.39 (+0.62), REGN: 375.74 (-2.61), CELG: 103.41 (-1.62)
Biotechnology Equities Under the Scanner - Exelixis, Novavax, Celgene, and Ariad Pharma
PR Newswire - Thu Jul 07, 7:00AM CDT
On Wednesday, July 06, 2016, the NASDAQ Composite ended the trading session at 4,859.16, up 0.75%; the Dow Jones Industrial Average edged 0.44% higher, to finish at 17,918.62; and the S&P 500 closed at 2,099.73, up 0.54%. The gains were broad based as eight out of nine sectors ended the session in positive. Stock-Callers.com has initiated coverage on the following equities: Exelixis Inc. (NASDAQ: EXEL), Novavax Inc. (NASDAQ: NVAX), Celgene Corporation (NASDAQ: CELG), and Ariad Pharmaceuticals Inc. (NASDAQ: ARIA). Learn more about these stocks by accessing their free notes at:
NVAX: 7.77 (+0.15), ARIA: 7.37 (-0.14), CELG: 103.41 (-1.62), EXEL: 8.15 (unch), CELGZ: 1.40 (-0.03)
SmarTrend Watching for Potential Pullback in Shares of Celgene After 3.49% Gain
Comtex SmarTrend(R) - Wed Jul 06, 11:56AM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $100.13 to a high of $104.94. Yesterday, the shares gained 3.5%, which took the trading range above the 3-day high of $101.39 on volume of 3.9 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
CELG: 103.41 (-1.62)
Watch for Celgene to Potentially Pullback After Gaining 3.49% Yesterday
Comtex SmarTrend(R) - Wed Jul 06, 11:56AM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $100.13 to a high of $104.94. Yesterday, the shares gained 3.5%, which took the trading range above the 3-day high of $101.39 on volume of 3.9 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
CELG: 103.41 (-1.62)
Amgen's Kyprolis Gains Approval in EU for Label Expansion
Zacks Equity Research - Zacks Investment Research - Wed Jul 06, 9:37AM CDT
Amgen's (AMGN) Kyprolis label has been expanded in the EU for the treatment of relapsed multiple myeloma patients.
AMGN: 160.18 (-0.92), ABBV: 64.35 (+0.19), BMY: 75.39 (+0.11), CELG: 103.41 (-1.62)
Blog Coverage Biotech Major Medivation Open to Takeover Talks
ACCESSWIRE - Wed Jul 06, 8:15AM CDT
LONDON, UK / ACCESSWIRE / July 6, 2016 / Active Wall St. blog coverage looks at the headline from Medivation Inc. (NASDAQ: MDVN) as the U.S. company signs confidentiality agreements with Paris-based Sanofi S.A. (NYSE: SNY), Pfizer Inc. (NYSE: PFE) and Celgene Corp. (NASDAQ: CELG) among others. Register with us now for your free membership and blog access at:
MDVN: 62.23 (+0.13), PFE: 36.15 (+0.03), ABBV: 64.35 (+0.19), SNY: 41.42 (+0.57), CELG: 103.41 (-1.62)
After Yesterday's Rally of 2.09% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Fri Jul 01, 12:32PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $98.25 to a high of $101.39. Yesterday, the shares gained 2.1%, which took the trading range above the 3-day high of $99.42 on volume of 1.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
CELG: 103.41 (-1.62)
Celgene Rises 2.09% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Fri Jul 01, 12:30PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $98.25 to a high of $101.39. Yesterday, the shares gained 2.1%, which took the trading range above the 3-day high of $99.42 on volume of 1.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
CELG: 103.41 (-1.62)
How Does Brexit Impact Healthcare Stocks?
Arpita Dutt - Zacks Investment Research - Mon Jun 27, 8:34AM CDT
While Brexit does create economic uncertainty and there could be some near-term volatility in the sector, the general verdict is that Brexit's impact on drug stocks will be limited.
VRTX: 90.10 (+1.14), BMRN: 88.59 (-2.90), ALXN: 125.30 (+0.88), GSK: 43.52 (+0.14), CELG: 103.41 (-1.62)
Learn how to target an 20% return on Chipotle Mexican Grill, or get option-trade ideas on Amgen, Celgene, Google Inc., and SolarEdge Technologies or any stock you choose
PR Newswire - Thu Jun 23, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for AMGN, CELG, CMG, GOOG, and SEDG.
SEDG: 19.82 (+0.14), CMG: 403.18 (+3.47), AMGN: 160.18 (-0.92), GOOGL: 727.20 (+9.42), GOOG: 715.09 (+9.46), CELGZ: 1.40 (-0.03), CELG: 103.41 (-1.62)
Prima Reports Favorable Initial Breast Cancer Study Data
Zacks Equity Research - Zacks Investment Research - Wed Jun 22, 2:30PM CDT
Prima BioMed Ltd (PBMD) announced initial data from a phase IIb chemo-immunotherapy study on IMP321 for the treatment of metastatic breast cancer.
PBMD: 0.92 (unch), ANIP: 55.38 (-1.13), RTRX: 18.47 (-0.18), CELG: 103.41 (-1.62)
Four NCI Cancer Centers Announce Landmark Research Consortium and Collaborations with Celgene
BusinessWire - Wed Jun 22, 6:30AM CDT
Today, The Abramson Cancer Center at the University of Pennsylvania, The Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, and The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai announced the establishment of a research consortium focused on accelerating the discovery and development of novel cancer therapeutics and diagnostics for the benefit of patients.
CELG: 103.41 (-1.62)
Celgene Set to Possibly Rebound After Yesterday's Selloff of 2.17%
Comtex SmarTrend(R) - Tue Jun 21, 11:55AM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $96.55 to a high of $99.80. Yesterday, the shares fell 2.2%, which took the trading range below the 3-day low of $98.22 on volume of 4.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
CELG: 103.41 (-1.62)
Watch for Shares of Celgene (CELG) to Approach Resistance at $101.34
Comtex SmarTrend(R) - Mon Jun 20, 8:47AM CDT
Celgene (NASDAQ:CELG) has opened bullishly above the pivot of $99.13 today and has reached the first level of resistance at $100.04. Should the shares continue to rise, the resistance pivots of $101.34 and $103.55 will be of interest.
CELG: 103.41 (-1.62)
Company News for June 16, 2016
Zacks Equity Research - Zacks Investment Research - Thu Jun 16, 9:10AM CDT
Companies in the News are: BOBE,TWTR,PN,EBIX,CELG
PN: 7.80 (+0.14), BOBE: 36.33 (+0.32), EBIX: 52.12 (+2.98), TWTR: 17.71 (-0.37), CELG: 103.41 (-1.62)
Celgene Announces Additional $3 Billion Share Repurchase Authorization
BusinessWire - Wed Jun 15, 6:30AM CDT
Celgene Corporation (NASDAQ:CELG) today announced that during its June meeting the Company's Board of Directors authorized the repurchase of up to an additional $3.0 billion of the Company's common stock.
CELG: 103.41 (-1.62), CELGZ: 1.40 (-0.03)
SmarTrend Watching for Potential Rebound in Shares of Celgene After 2.63% Loss
Comtex SmarTrend(R) - Fri Jun 10, 12:32PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $103.26 to a high of $105.47. Yesterday, the shares fell 2.6%, which took the trading range below the 3-day low of $105.65 on volume of 2.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
CELG: 103.41 (-1.62)
Watch for Celgene to Potentially Rebound After Falling 2.63% Yesterday
Comtex SmarTrend(R) - Fri Jun 10, 12:30PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $103.26 to a high of $105.47. Yesterday, the shares fell 2.6%, which took the trading range below the 3-day low of $105.65 on volume of 2.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
CELG: 103.41 (-1.62)
Acceleron and Celgene Announce Updated Results from an Ongoing Phase 2 Study of Luspatercept in Myelodysplastic Syndromes at the 21st Congress of the European Hematology Association
BusinessWire - Fri Jun 10, 6:00AM CDT
--- Acceleron to host conference call and live webcast today at 8:00 a.m. EDT (2:00 p.m. CEST) -
XLRN: 34.35 (-0.40), CELGZ: 1.40 (-0.03), CELG: 103.41 (-1.62)
Celgene Announces Presentations of Investigational Studies in Blood Cancers at EHA 2016
BusinessWire - Thu Jun 09, 6:30AM CDT
Celgene Corporation (NASDAQ:CELG) today announced that more than 40 presentations reporting on investigational studies in blood cancers will be presented during the 21st European Hematology Association annual meeting in Copenhagen, Denmark, from June 9-12, 2016.
CELG: 103.41 (-1.62), CELGZ: 1.40 (-0.03)
